Research programme: cancer therapeutics and diagnostic agents - Siamab Therapeutics

Drug Profile

Research programme: cancer therapeutics and diagnostic agents - Siamab Therapeutics

Alternative Names: Anti-glycan antibodies; Anti-Neu5Gc antibodies - Sialix; Anti-Sialyl-Tn antibodies; Anti-Sialyl-Tn monoclonal antibodies; Anti-STn antibodies; Humanised anti-Sialyl-Tn anti-CD3 bispecific antibodies; SIA01-ADC; SIA02-ADC; ST1; ST1 antibody drug conjugate programme

Latest Information Update: 02 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sialix
  • Developer Massachusetts General Hospital; Siamab Therapeutics
  • Class Antineoplastics; Bispecific antibodies; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action Polysaccharide inhibitors; Sialosyl Tn antigen inhibitors; Tumour-associated carbohydrate antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Breast cancer; Colorectal cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Solid tumours
  • Research Cancer

Most Recent Events

  • 30 Oct 2017 Pharmacodynamics and adverse events data from preclinical studies in Solid tumours presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2017
  • 26 Oct 2017 Pharmacodynamics, pharmacokinetics and adverse events data from preclinical studies in Solid tumours presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2017
  • 04 Oct 2017 Simab and Boehringer Ingelheim enter into a collaboration agreement to develop anti-cancer therapeutics targeting tumours associated carbohydrate antigens
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top